Molecular structure of Lapatinib ditosylate, CAS Number: 388082-78-8
Lapatinib ditosylate (CAS 388082-78-8)
See product citations (15)
Alternate Names:
Tykerb Ditosylate; GW-572016; Tyverb
Application:
Lapatinib ditosylate is a selective and effective inhibitor of ErbB-2 and EGFR dual tyrosine kinases
CAS Number:
388082-78-8
Purity:
>99%
Molecular Weight:
925.46
Molecular Formula:
C29H26ClFN4O4S•2C7H8O3S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Lapatinib Ditosylate, a selective and potent inhibitor, targets the dual tyrosine kinases ErbB-2 and EGFR, which are growth-promoting factors overexpressed in certain breast cancer cell lines. Extensive research studies have demonstrated Lapatinib Ditosylate′s capability to hinder breast cancer cell proliferation. This compound is a dual inhibitor, acting on both the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) tyrosine kinases. The mechanism of action involves Lapatinib Ditosylate binding to the ATP binding pocket of the EGFR and HER2 tyrosine kinases, thereby impeding their activation. This inhibition disrupts downstream signaling pathways for cancer cell growth and proliferation, ultimately halting their progression.
Lapatinib ditosylate (CAS 388082-78-8) References
- Lapatinib ditosylate GlaxoSmithKline. | Kim, TE. and Murren, JR. 2003. IDrugs. 6: 886-93. PMID: 12964069
- A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer. | Nelson, MH. and Dolder, CR. 2007. Ther Clin Risk Manag. 3: 665-73. PMID: 18472989
- Lessons learned from independent central review. | Ford, R., et al. 2009. Eur J Cancer. 45: 268-74. PMID: 19101138
- Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer. | Awada, A., et al. 2011. Drugs Today (Barc). 47: 335-45. PMID: 22013564
- Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience. | Dogan, E., et al. 2012. Med Oncol. 29: 3232-9. PMID: 22729366
- Cancer-linked targets modulated by curcumin. | Hasima, N. and Aggarwal, BB. 2012. Int J Biochem Mol Biol. 3: 328-51. PMID: 23301199
- Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells. | Yu, T., et al. 2016. Oncotarget. 7: 79089-79100. PMID: 27738326
- The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress. | Bahrami, A., et al. 2018. J Cell Biochem. 119: 213-222. PMID: 28513879
- Distribution analysis of epertinib in brain metastasis of HER2-positive breast cancer by imaging mass spectrometry and prospect for antitumor activity. | Tanaka, Y., et al. 2018. Sci Rep. 8: 343. PMID: 29321587
- Preparation of lapatinib ditosylate solid dispersions using solvent rotary evaporation and hot melt extrusion for solubility and dissolution enhancement. | Hu, XY., et al. 2018. Int J Pharm. 552: 154-163. PMID: 30268849
- Coupling of salting-out assisted liquid-liquid extraction with on-line stacking for the analysis of tyrosine kinase inhibitors in human plasma by capillary zone electrophoresis. | Ahmed, OS., et al. 2018. J Chromatogr A. 1579: 121-128. PMID: 30361035
- Liposomal Lapatinib in Combination with Low-Dose Photodynamic Therapy for the Treatment of Glioma. | Fisher, C., et al. 2019. J Clin Med. 8: PMID: 31847378
- In silico structure prediction, molecular docking and dynamic simulation studies on G Protein-Coupled Receptor 116: a novel insight into breast cancer therapy. | Muthiah, I., et al. 2021. J Biomol Struct Dyn. 39: 4807-4815. PMID: 32580684
- Lapatinib ditosylate rescues memory impairment in D-galactose/ovariectomized rats: Potential repositioning of an anti-cancer drug for the treatment of Alzheimer's disease. | Mansour, HM., et al. 2021. Exp Neurol. 341: 113697. PMID: 33727095
- Inhibition of mitochondrial pyruvate carrier 1 by lapatinib ditosylate mitigates Alzheimer's-like disease in D-galactose/ovariectomized rats. | Mansour, HM., et al. 2021. Neurochem Int. 150: 105178. PMID: 34481907
Inhibitor of:
EGF, EGFR, ErbB, EXT1, Fnk, folliculin, gankyrin, GFRA (GDNF family receptor alpha), Gm960, KRAP, Neu, pki α, and PKR1.Activator of:
FOG.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Lapatinib ditosylate, 5 mg | sc-202205B | 5 mg | $48.00 | |||
Lapatinib ditosylate, 10 mg | sc-202205 | 10 mg | $75.00 | |||
Lapatinib ditosylate, 25 mg | sc-202205A | 25 mg | $115.00 |